Clinical Trial Update: Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children [Phase 1]

View source ↗

Summary

Phase 1 safety assessment of the probiotic Lactobacillus salivarius CECT5713 in 6-month-old children has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infection

Drugs mentioned

• Lactobacillus salivarius CECT5713 (Lactobacillus salivarius CECT5713)

Snippet

Sponsor: Puleva Biotech | Conditions: Infection | Phase 1 | Status: COMPLETED